As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...

Vislink Technologies, Inc. ( NASDAQ: VISL) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Mickey Miller - Chief Executive Officer Mike Bond - Chief Financial Officer ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Bristol-Myers Squibb's Cobenfy comes out as the major beneficiary and will ... and the next steps taken by AbbVie will tell ...

With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...

Too many of us are dying, presenting with it too late ... The Cancer Equals campaign Greene is supporting was launched by ...

Sales of blood cancer drug Revlimid, which is now facing generic competition, dropped 11% to $1.41 billion in the quarter, ...

Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY / ACCESSWIRE / October 23, 2024 / Evotec SE ...